Back to News
Market Impact: 0.25
Aligos Therapeutics, Inc. Reports Third Quarter 2026 Financial Results
Source: Nasdaq
Corporate EarningsHealthcare & BiotechCompany Fundamentals
Aligos Therapeutics reported $31.1 million in cash, cash equivalents and investments as of September 30, 2026, down from $77.8 million at December 31, 2025—a decrease of $46.7 million. The available article text provides no additional results or outlook details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.20
Ticker Sentiment
ALGS-0.35
More News
- Further turmoil could be in store for tech stocks. What to watch in the week ahead
- Elon Musk once said the Cybertruck would be Tesla’s ‘best product ever.’ Now he’s winding down production
- AI stocks hammered by midterm shock as data center buildout becomes a 'war of attrition'
- Fox completes its $22B acquisition of Roku
- Elanco Shares Jump After Q3 Beat and Outlook Raise
- FTSE 100 today: Stocks slump as global tech rout deepens